<DOC>
	<DOCNO>NCT01739244</DOCNO>
	<brief_summary>The aim dose-finding clinical trial evaluate systemic tolerability , local tolerability intraocular pressure lower effect three different dos SYL040012 subject ocular hypertension open-angle glaucoma .</brief_summary>
	<brief_title>Dose Finding Clinical Trial With SYL040012 Evaluate Tolerability Effect Intraocular Pressure Subjects With Ocular Hypertension Open Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Subjects must provide sign informed consent prior participation studyrelated procedure . Male female subject good fair general health assess investigator . ≥18 year age . Previous history newly diagnose elevate IOP ( ≥21 mmHg ) without openangle glaucoma eye . Normal result , result typical openangle glaucoma follow assessment eye available result write within last 3 month prior baseline period i.e . 4 month Day 1 , condition new ocular sign symptom ( e.g . mark deterioration vision , eye pain ) occur since would justify repeat examination : Visual field 242 equivalent Optical coherence tomography ( OCT ) Best correct visual acuity ≥0.5 ( 20/40 ) Snellen chart , ≤ 0.3 logMAR Schirmer test ( lacrimation ) Funduscopy Pregnant breastfeed female positive pregnancy test . Females childbearing potential use medically acceptable contraceptive method selection hole study . Females childbearing potential willing use medically acceptable contraceptive method enrolment followup visit . Any current disease condition might compromise respiratory , cardiovascular , endocrine , neurological , haematological , renal , gastrointestinal function . Previous chronic process rebound characteristic could interfere study accord investigator 's judgment . Body temperature . Intolerability component SYL040012 placebo . Unable comply clinical trial requirement judge investigator . Beta blocker corticosteroid use ( cutaneous intraarticular ) treatment concurrent disease , even sporadically , ocular nasal vasoconstrictor treatment last 15 day prior first investigational product administration Previous refractive surgery ; cataract extraction last 6 month Previous surgery glaucoma . Participation clinical trial within 2 month enrolment visit Use investigational product within 60 day enrolment visit . Other drug treatment concurrent diseases allow . However , dosage keep constant throughout study . Use contact lens last 7 day prior first investigational product administration wear contact lenses throughout trial History ocular infection inflammation within last 3 month enrolment visit Angleclosure pigmentary glaucoma . Chronic current acute eye diseases scleritis , uveitis , blepharitis , conjunctivitis , ocular Herpes simplex virus infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Open Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>IOP</keyword>
	<keyword>RNAi</keyword>
	<keyword>siRNA</keyword>
	<keyword>beta inhibitor</keyword>
</DOC>